Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Quizartinib is a tyrosine kinase inhibitor selectively targeting the FMS-like tyrosine kinase 3 (FLT3) receptor that has been developed for the treatment of acute myeloid leukaemia (AML). The Phase 3 QuANTUM-R study investigated the efficacy of quizartinib monotherapy in patients with relapsed/refra...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Drug Investig
Glavni autori: Martínez-Cuadrón, David, Rodríguez-Macías, Gabriela, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Montesinos, Pau
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Practical Application
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035240/
https://ncbi.nlm.nih.gov/pubmed/31912423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00881-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items